494 related articles for article (PubMed ID: 15591654)
1. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
2. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
Wesierska-Gadek J; Gueorguieva M; Horky M
Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
[TBL] [Abstract][Full Text] [Related]
4. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Wesierska-Gadek J; Borza A; Komina O; Maurer M
Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
[TBL] [Abstract][Full Text] [Related]
6. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
Maurer M; Komina O; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():250-6. PubMed ID: 19723062
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
8. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
Komina O; Wesierska-Gadek J
Biochem Pharmacol; 2008 Dec; 76(11):1554-62. PubMed ID: 18761329
[TBL] [Abstract][Full Text] [Related]
9. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
[TBL] [Abstract][Full Text] [Related]
10. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
Wesierska-Gadek J; Gueorguieva M; Kramer MP; Ranftler C; Sarg B; Lindner H
J Cell Biochem; 2007 Dec; 102(6):1405-19. PubMed ID: 17975794
[TBL] [Abstract][Full Text] [Related]
11. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
Schang LM; Phillips J; Schaffer PA
J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Wesierska-Gadek J; Kramer MP; Maurer M
Food Chem Toxicol; 2008 Apr; 46(4):1327-33. PubMed ID: 17933449
[TBL] [Abstract][Full Text] [Related]
14. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
[TBL] [Abstract][Full Text] [Related]
15. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Wesierska-Gadek J; Schmitz ML; Ranftler C
J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
[TBL] [Abstract][Full Text] [Related]
16. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
[TBL] [Abstract][Full Text] [Related]
17. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
18. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Zulehner N; Maurer M; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
[TBL] [Abstract][Full Text] [Related]
19. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
[TBL] [Abstract][Full Text] [Related]
20. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]